skip to Main Content

Ambry to Present New Data Showing That up to 30% of Cancer Risk Carriers Are Missed by Current Testing Guidelines at the 2017 ASCO Meeting

Newsfeed image, light gray text on dark gray background
Ambry Genetics (Ambry), a leading clinical genetics testing lab, is showcasing groundbreaking research in a platform and a poster presentation at the 2017 American Society of Clinical Oncologists (ASCO) Annual Meeting. These presentations will shed light on hereditary pancreatic, thyroid and breast and colon cancers and demonstrate that a larger segment of the population may benefit from genetic testing than is reported using current genetic testing guidelines.

The platform presentation, “Germline Genetic Testing in Unselected Pancreatic Ductal Adenocarcinoma (PDAC) Patients,” reports findings from Ambry’s collaborative study with University of Pittsburgh, Beth Israel Deaconess Medical Center and HonorHealth/TGen. Read more . . .

Back To Top